Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose vials for injection via syringe -- a move to increase production of these popular drugs and decrease both costs of manufacturing and costs for the patient.
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says
Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on average 50.3 lb (22.8 kg) while those treated with semaglutide lost 33.1 lb (15 kg), translating to a 47% greater relative weight loss with tirzepatide.
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Key Takeaways Patients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new clinical study.Zepbound patients lost an average 20% of their body weight compared with roughly 14% for those on Wegovy.
Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Topline Results
Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.
LILLY'S TIRZEPATIDE SUPERIOR TO WEGOVY® (SEMAGLUTIDE) IN HEAD-TO-HEAD TRIAL SHOWING AN AVERAGE WEIGHT LOSS OF 20.2% VS. 13.7%
Eli Lilly Canada today announced topline results from the SURMOUNT-5 Phase 3b open-label randomized clinical trial. Tirzepatide provided a 47% greater relative weight loss compared to Wegovy® (semaglutide).
Eli Lilly's GLP-1 outdoes Novo Nordisk's in trial
Adults taking Eli Lilly's Zepbound lost 47% more weight on average than those on Novo Nordisk's Wegovy, Lilly reported from the first head-to-head trial comparing the two blockbuster GLP-1 obesity drugs.
Eli Lilly's Zepbound defeats Novo Nordisk's Wegovy in head-to-head weight loss trial
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market and patients wondered which company’s products were more effective, there | Eli Lilly revealed results from a study that showed its obesity drug Zepbound was 47% more effective than Novo’s Wegovy in helping patients lose weight.
Zepbound Tops Wegovy for Weight Loss in Eli Lilly Study
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nor
Zepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds
Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide),
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients on obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.
BioSpace
1d
Lilly Pumps $3B Into Wisconsin Site as Compounders Close In on Tirzepatide
Eli Lilly is aggressively ramping up its manufacturing capacity for tirzepatide as compounding pharmacies continue to ...
2d
on MSN
Lilly's Zepbound will first be given in the UK to those with 'highest clinical need'
The initial rollout of Eli Lilly's weight loss drug Zepbound in the UK will first go to those with the great clinical need ...
2d
Eli Lilly to spend $3 billion, add 750 employees in Kenosha County expansion
Drugmaker Eli Lilly and Co. will invest $3 billion and add 750 employees in Kenosha County as the company expands a plant it ...
STAT
2d
U.K. to restrict Eli Lilly’s obesity drug to patients with greatest need
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback